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Dear Editor, 
We have read the paper by Mock et al.1 assessing the risk of major bleeding in a cohort of real-life 
patients receiving ibrutinib with great interest. Their findings prompt serious concerns regarding 
major bleeding risk, particularly among patients that were excluded from the population of trials 
which are the cornerstone of the ibrutinib use today due to need for concomitant therapies. 
However, these patients surely exist in the real-life setting as shown in the present study.  
Although seemingly counterintuitive, platelet counts <50 K/µL did not seem to be associated with 
higher major bleeding risk in the univarate analysis and were not considered further in the 
multivariate setting. As shown in the Table 4, platelet counts were not significantly associated with 
unwanted outcome [HR 1.8, 95% confidence interval (0.4 – 8.3)], although hazard associated with 
thrombocytopenia was non-significantly increased on average. It is logical and biologically plausible 
that lower platelet counts would predispose to major bleeding risk, especially if platelet function is 
blunted by the use of ibrutinib. In our opinion, protective effects of higher platelets in the current 
study could be abolished by the concurrent use of antiplatelet and anticoagulant drugs which 
commonly occurs only in a subgroup of patients with adequate platelet counts (i.e. >50 K/µL). Lower 
platelet counts are a general contraindication for full dose anticoagulant therapy2 and both 
antiplatelet and anticoagulant drugs are highly likely to be avoided in this context. Thus, presented 
lack of association of platelet counts with major bleeding risk is very likely to be confounded by 
concurrent medications predominantly used only in patients with higher platelet counts. Reported 
finding should by no means be interpreted as a safe level of thrombocytopenia regarding bleeding 
risk.  
We consider that presented work provides valuable insight into the real-life profile of patients 
receiving ibrutinib. It also highlights unacceptably high major bleeding risk in a subgroup of patients 
exposed to ibrutinib, antiplatelet and anticoagulant therapy at the same time. We feel that 
assessment of factors associated with bleeding risk would benefit from providing additional 
information regarding proportions of patients with platelet counts >50 K/µL and <50 K/µL receiving 
concurrent antiplatelet/anticoagulant drugs, how are platelet counts associated with major bleeding 
risk in subgroups of patients stratified by exposure to these drugs, and whether effects of platelet 
counts on outcome depend on concurrent anticoagulant/antiplatelet use in the multivariate analysis. 
We hope that authors could provide such analyses. 
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